Use of laboratory animals to identify carcinogenic potential of chemicals, mixtures, and other agents has a modern history of greater than 40 years from which much useful scientific and public health information can be derived. While laboratory animals differ from humans in some respects that may affect responses to hazardous exposures, use of such models is based on experimental evidence indicating that there are more genetic, genomic, physiological, biochemical, and metabolic similarities than differences among mammalian species. Issues of concordance of responses between rodent species and between rodents and humans as well as repeatability and site-specificity are important considerations in evaluating laboratory animal carcinogenicity results. Variables in experimental design such as animal strain, diet, route of exposure, and study duration as well as single-site versus multisite carcinogenic responses all influence interpretation and intelligent use of study data. Similarities and differences in site-specific laboratory animal and corresponding human cancers should also be considered in study evaluation. Recent attempts to explore genetically engineered mice and to humanize the mouse for more relevant identification of carcinogen hazard identification have yielded mixed results. In the end we are confronted by the realization that virtually all animal cancer models are useful but imperfect surrogates for humans. Assuming the percentage of chemicals currently in commerce that are estimated to be potent animal or human carcinogens is quite low, the task of identifying agents with significant carcinogenic potential is daunting and important. The biological conundrum of scientific debate regarding the relevance of carcinogenicity studies in laboratory animals is likely to continue. Nonetheless public health considerations must take precedence when deciding human safety issues.
Abdo, K.M., and Kari, F.W. (1996). The sensitivity of the NTP bioassay for carcinogen hazard evaluation can be modulated by dietary restriction. Exp-Toxicol-Pathol48, 129—37.
2.
Afip (1995). Tumors of the Lower Respiratory Tract, Vol. AFIP Fascicle 13, Armed Forces Institute of Pathology, Washington, DC.
3.
Anna, C.H., Sills, R.C., Foley, J.F., Stockton, P.S., Ton, T.V., and Devereux, T.R. (2000). Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res60, 2864—8.
4.
Bannasch, P., Haertel, T., and Su, Q. (2003). Significance of hepatic preneoplasia in risk identification and early detection of neoplasia. Toxicol Pathol31, 134—9.
5.
Bannasch, P., and Zerban, H. (1992). Predictive value of hepatic preneoplastic lesions as indicators of carcinogenic response. IARC Sci Publ, 389— 427.
6.
Bhave, M.R., Wilson, M.J., and Waalkes, M.P. (1988). Methylation status and organization of the metallothionein-I gene in livers and testes of strains of mice resistant and susceptible to cadmium. Toxicology50, 231—45.
7.
Bucher, J. (2002). The National Toxicology Program rodent bioassay: designs, interpretations, and scientific contributions. Ann NY Acad Sci982, 198— 207.
8.
Cardiff, R.D., Anver, M.R., Gusterson, B.A., Hennighausen, L., Jensen, R.A., Merino, M.J., Rehm, S., Russo, J., Tavassoli, F.A., Wakefield, L.M., Ward, J.M., and Green, J.E. (2000). The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting . Oncogene19, 968—88.
9.
Chadeneau, C., Siegel, P., Harley, C.B., Muller, W.J., and Bacchetti, S. (1995). Telomerase activity in normal and malignant murine tissues. Oncogene11, 893—8.
10.
Cohen, S.M. (1995). Human relevance of animal carcinogenicity studies . Regul Toxicol Pharmacol21, 75—80; discussion 81—6.
11.
Dass, S.B., Hammons, G.J., Bucci, T.J., Heflich, R.H., and Casciano, D.A. (1998). Susceptibility of C57BL/6 mice to tumorigenicity induced by dimethylnitrosamine and 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine in the neonatal bioassay. Cancer Lett124, 105—10.
12.
De Souza, A.T., Yamada, T., Mills, J.J., and Jirtle, R.L. (1997). Imprinted genes in liver carcinogenesis. FASEB J11, 60—7.
13.
Devereux, T.R., White, C.M., Sills, R.C., Bucher, J.R., Maronpot, R.R., and Anderson, M.W. (1994). Low frequency of H-ras mutations in hepatocellular adenomas and carcinomas and in hepatoblastomas from B6C3F1 mice exposed to oxazepam in the diet. Carcinogenesis15, 1083—7.
14.
DiPaolo, J.A. (1983). Relative difficulties in transforming human and animal cells in vitro. J Natl Cancer Inst70, 3—8.
15.
Drinkwater, N.R., and Ginsler, J.J. (1986). Genetic control of hepatocarcinogenesis in C57BL/6J and C3H/HeJ inbred mice. Carcinogenesis7, 1701—7.
16.
Eustis, S.L., and Boorman, G.A. (1990). Exocrine Pancreas. In Pathology of the Fischer Rat. Reference and Atlas ( G. A. Boorman, S. L. Eustis, M. R. Elwell, C. A. Montgomery, Jr., and W. F. MacKenzie, eds.), pp. 102—103. Academic Press, Inc., New York.
17.
Farber, E., and Sarma, D.S. (1987). Hepatocarcinogenesis: a dynamic cellular perspective . Lab Invest56, 4—22.
18.
Festing, M.F. (1995). Use of a multistrain assay could improve the NTP carcinogenesis bioassay. Environ Health Perspect103, 44—52.
19.
Freireich, E., Gehan, E., Rall, D., Schmidt, L., and Skipper, H. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep50, 219—44.
20.
Frith, C.H., Baetcke, K.P., Nelson, C.J., and Schieferstein, G. (1980). Sequential morphogenesis of liver tumors in mice given benzidine dihydrochloride. Eur J Cancer16, 1205—16.
21.
Fu, X.X., Su, C.Y., Lee, Y., Hintz, R., Biempica, L., Snyder, R., and Rogler, C.E. (1988). Insulinlike growth factor II expression and oval cell proliferation associated with hepatocarcinogenesis in woodchuck hepatitis virus carriers. J Virol62, 3422—30.
22.
Fung, V.A., Barrett, J.C., and Huff, J. (1995). The carcinogenesis bioassay in perspective: application in identifying human cancer hazards. Environ Health Perspect103, 680—3.
23.
Ginsberg, G.L., Pepelko, W.E., Goble, R.L., and Hattis, D.B. (1996). Comparison of contact site cancer potency across dose routes: case study with epichlorohydrin. Risk Anal16, 667—81.
24.
Goldfarb, S., and Pugh, T.D. (1986). Multistage rodent hepatocarcinogenesis. Prog Liver Dis8, 597—620.
25.
Greenlee, W.F., Conolly, R.B., and Anderson, M.E. (2003). New directions for human health effects research at CIIT: a systems biology perspective. CIIT Activities23, 1—5.
26.
Gregory, A.R. (1988). Species comparisons in evaluating carcinogenicity in humans. Regul Toxicol Pharmacol8, 160—90.
27.
Griesemer, R.A., and Eustis, S.L. (1994). Gender differences in animal bioassays for carcinogenicity . J Occup Med36, 855—9.
28.
Grisham, J.W. (1996). Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis18, 59—81.
29.
Hailey, J.R., Haseman, J.K., Bucher, J.R., Radovsky, A.E., Malarkey, D.E., Miller, R.T., Nyska, A., and Maronpot, R.R. (1998). Impact of Helicobacter hepaticus infection in B6C3F1 mice from twelve National Toxicology Program two-year carcinogenesis studies. Toxicol Pathol26, 602— 11.
30.
Hanigan, M., Kemp, C., Ginsler, J., and Drinkwater, N. (1988). Rapid growth of preneoplastic lesions in hepatocarcinogen-sensitive C3H/HeJ male mice relative to C57BL/6J male mice. Carcinogenesis9, 885—90.
31.
Harada, T., Enomoto, A., Boorman, G.A., and Maronpot, R.R. (1999). Liver and Gallbladder. In Pathology of the Mouse (R. R. Maronpot, ed.), p. 146. Cache River Press, Vienna, IL.
32.
Haseman, J., Melnick, R., Tomatis, L., and Huff, J. (2001). Carcinogenesis bioassays: study duration and biological relevance. Food Chem Toxicol39, 739—44.
33.
Haseman, J.K. (1983). Patterns of tumor incidence in two-year cancer bioassay feeding studies in Fischer 344 rats. Fundam Appl Toxicol3, 1—9.
34.
Haseman, J.K., and Huff, J.E. (1987). Species correlation in long-term carcinogenicity studies. Cancer Lett37, 125—32.
35.
Hegi, M.E., Soderkvist, P., Foley, J.F., Schoonhoven, R., Swenberg, J.A., Kari, F., Maronpot, R., Anderson, M.W., and Wiseman, R.W. (1993). Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis14, 803—10.
36.
Hoel, D., Haseman, J., Hogan, M., Huff, J., and McConnell, E. (1988). The impact of toxicity on carcinogenicity studies: implications for risk assessment. Carcinogenesis9, 2045—52.
37.
Hsia, C.C., Evarts, R.P., Nakatsukasa, H., Marsden, E.R., and Thorgeirsson, S.S. (1992). Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology16, 1327—33.
38.
Hsia, C.C., Thorgeirsson, S.S., and Tabor, E. (1994). Expression of hepatitis B surface and core antigens and transforming growth factor-alpha in “oval cells” of the liver in patients with hepatocellular carcinoma. J Med Virol43, 216—21.
39.
Huff, J. (1992). Applicability to humans of rodent-specific sites of chemical carcinogenicity: tumors of the forestomach and of the Harderian, preputial, and zymbal glands induced by benzene. J Occup Med Toxicol1, 109— 41.
40.
Huff, J. (1993a). Absence of morphologic correlation between chemical toxicity and chemical carcinogenesis. Environ Health Perspect101(Suppl 5), 45—53.
41.
Huff, J. (1993b). Chemicals and cancer in humans: first evidence in experimental animals. Environ Health Perspect100, 201—10.
42.
Huff, J. (1994). Chemicals causally associated with cancers in humans and in laboratory animals: a perfect concordance. In Carcinogenesis (M. Waalkes and J. Ward, eds.), Vol. Chapter 2, pp. 25—37. Raven Press, New York.
43.
Huff, J. (1995). Mechanisms, chemical carcinogenesis, and risk assessment: cell proliferation and cancer. Am J Ind Med27, 293—300.
44.
Huff, J. (1999). Long-term chemical carcinogenesis bioassays predict human cancer hazards. Issues, controversies, and uncertainties. Ann NY Acad Sci895, 56—79.
45.
Huff, J. (2002). Chemicals studied and evaluated in long-term carcinogenesis bioassays by both the Ramazzini Foundation and the National Toxicology Program: in tribute to “Cesare Maltoni and David Rall.” Ann NY Acad Sci982, 208—30.
46.
Huff, J., Cirvello, J., Haseman, J., and Bucher, J. (1991). Chemicals associated with site-specific neoplasia in 1394 long-term carcinogenesis experiments in laboratory rodents. Environ Health Perspect93, 247—70.
Johnson, F.M. (2003). Are rodent carcinogenicity bioassays relevant? Banging the drum softly. Toxicol Pathol31, 350—2.
49.
Kaufmann, W., Mackenzie, S., and Kaufman, D. (1985). Quantitative relationship between hepatocytic neoplasms and islands of cellular alteration during hepatocarcinogenesis in the male F344 rat. AJP119, 171—4.
50.
Keenan, K.P., Ballam, G.C., Soper, K.A., Laroque, P., Coleman, J.B., and Dixit, R. (1999). Diet, caloric restriction, and the rodent bioassay . Toxicol Sci52, 24—34.
51.
Kemp, C.J., and Drinkwater, N.R. (1989). Genetic variation in liver tumor susceptibility, plasma testosterone levels, and androgen receptor binding in six inbred strains of mice. Cancer Res49, 5044—7.
52.
Kennedy, S.M., Macgeogh, C., Jaffe, R., and Spurr, N.K. (1994). Overexpression of the oncoprotein p53 in primary hepatic tumors of childhood does not correlate with gene mutations. Hum Pathol25, 438—42.
53.
Kress, S., Konig, J., Schweizer, J., Lohrke, H., Bauer-Hofmann, R., and Schwarz, M. (1992). p53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol Carcinog6, 148—58.
54.
Lee, G.H., and Drinkwater, N.R. (1995a). The Hcr (hepatocarcinogen resistance) loci of DBA/2J mice partially suppress phenotypic expression of the Hcs (hepatocarcinogen sensitivity) loci of C3H/HeJ mice. Carcinogenesis16, 1993—6.
55.
Lee, G.H., and Drinkwater, N.R. (1995b). Hepatocarcinogenesis in BXH recombinant inbred strains of mice: analysis of diverse phenotypic effects of the hepatocarcinogen sensitivity loci. Mol Carcinog14, 190—7.
56.
Lovell, D.P., van Iersel, M., Walters, D.G., Price, R.J., and Lake, B.G. (1999). Genetic variation in the metabolism of coumarin in mouse liver. Pharmacogenetics9, 239—50.
57.
Maltoni, C. (1995). The contribution of experimental [animal] studies to the control of industrial carcinogenesis. Appl Occup Environ Hyg10, 749—60.
58.
Maltoni, C., and Scarnato, C. (1979). First experimental demonstration of the carcinogenic effects of benzene: long-term bioassays on Sprague-Dawley rats by oral administration . Med Lav70, 352—7.
59.
Maronpot, R., Haseman, J., Boorman, G., Eustis, S., Rao, G., and Huff, J. (1987). Liver lesions in B6C3F1 mice: the National Toxicology Program experience and position. Arch Toxicol10(Suppl), 10—26.
60.
Maronpot, R.R., Montgomery, C.A. Jr. , Boorman, G.A., and McConnell , E.E. (1986). National Toxicology Program nomenclature for hepatoproliferative lesions of rats. Toxicol Pathol14, 263—73.
61.
Marx, J. (2003). Building better mouse models for studying cancer . Science299, 1972—5.
62.
Melnick, R. (1992). Does chemically induced hepatocyte proliferation predict liver carcinogenesis? FASEB J6, 2698—706.
63.
Melnick, R. (2002). Carcinogenicity and mechanistic insights on the behavior of epoxides and epoxide-forming chemicals. Ann NY Acad Sci982, 177— 89.
64.
Melnick, R., and Huff, J. (1993). Liver carcinogenesis is not a predicted outcome of chemically induced hepatocyte proliferation. Toxicol Ind Health9, 415— 38.
65.
Melnick, R., Kohn, M., Dunnick, J., and Leininger, J. (1998). Regenerative hyperplasia is not required for liver tumor induction in female B6C3F1 mice exposed to trihalomethanes. Toxicol Appl Pharmacol148, 137—47.
66.
Monro, A. (1993). How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans? Adverse Drug React Toxicol Rev12, 5—34.
67.
National Toxicology Program (2002). 10th Report on Carcinogens, pp. III-8 and III-257. National Institution of Environmental Health Sciences, U.S. Department of Health and Human Services, Research Triangle Park, NC.
68.
Paules, R. (2003). Phenotypic anchoring: linking cause and effect . Environ Health Perspect111, A338—9.
69.
Popper, H., Maltoni, C., and Selikoff, I. (1981). Vinyl chloride-induced hepatic lesions in man and rodents. A Comparison. Liver1, 7—20.
70.
Popper, H., Thung, S.N., McMahon, B.J., Lanier, A.P., Hawkins, I., and Alberts, S.R. (1988). Evolution of hepatocellular carcinoma associated with chronic hepatitis B virus infection in Alaskan Eskimos. Arch Pathol Lab Med112, 498—504.
71.
Pritchard, J.B., French, J.E., Davis, B.J., and Haseman, J.K. (2003). The role of transgenic mouse models in carcinogen identification. Environ Health Perspect111, 444—54.
72.
Prowse, K.R., and Greider, C.W. (1995). Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc Natl Acad Sci USA92, 4818—22.
Rall, D.P., Hogan, M.D., Huff, J.E., Schwetz, B.A., and Tennant, R.W. (1987). Alternatives to using human experience in assessing health risks. Annu Rev Public Health8, 355—85.
75.
Ray, J.S., Harbison, M.L., McClain, R.M., and Goodman, J.I. (1994). Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse live tumors. Mol Carcinog9, 155—66.
76.
Scarpelli, D.G. (1988). The Pancreas. In Pathology (E. Rubin and J. L. Farber, eds.), p. 819. J. B. Lippincott Company, Philadelphia .
77.
Schach von Wittenau, M., and Estes, P.C. (1983). The redundancy of mouse carcinogenicity bioassays . Fundam Appl Toxicol3, 631—9.
78.
Schulte-Hermann, R., Bursch, W., and Grasl-Kraupp, B. (1995). Active cell death (apoptosis) in liver biology and disease. Prog Liver Dis13, 1—35.
79.
Schut, H.A., Loeb, T.R., Grimes, L.A., and Stoner, G.D. (1983). Distribution, elimination, and test for carcinogenicity of 2,6-dinitrotoluene after intraperitoneal and oral administration to strain a mice. J Toxicol Environ Health12, 659—70.
80.
Sell, S., and Dunsford, H.A. (1989). Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am J Pathol134, 1347—63.
81.
Sipowicz, M.A., Weghorst, C.M., Shiao, Y.H., Buzard, G.S., Calvert, R.J., Anver, M.R., Anderson, L.M., and Rice, J.M. (1997). Lack of p53 and ras mutations in Helicobacter hepaticus-induced liver tumors in A/JCr mice. Carcinogenesis18, 233—6.
82.
Soffritti, M., Belpoggi, F., Minardi, F., and Maltoni, C. (2002). Ramazzini Foundation cancer program: history and major projects, life-span carcinogenicity bioassay design, chemicals studies, and results. Ann NY Acad Sci982, 26—45.
83.
Su, Q., and Bannasch, P. (2003). Relevance of hepatic preneoplasia for human hepatocarcinogenesis . Toxicol Pathol31, 126—33.
84.
Takahashi, M., Dinse, G.E., Foley, J.F., Hardisty, J.F., and Maronpot, R.R. (2002). Comparative prevalence, multiplicity, and progression of spontaneous and vinyl carbamate-induced liver lesions in five strains of male mice. Toxicol Pathol30, 599—605.
85.
Tennant, R.W., Elwell, M.R., Spalding, J.W., and Griesemer, R.A. (1991). Evidence that toxic injury is not always associated with induction of chemical carcinogenesis. Mol Carcinog4, 420—40.
86.
Tomatis, L. (1979). The predictive value of rodent carcinogenicity tests in the evaluation of human risks. Annu Rev Pharmacol Toxicol19, 511—30.
87.
Tomatis, L., Aitio, A., Wilbourn, J., and Shuker, L. (1989). Human carcinogens so far identified. Jpn J Cancer Res80, 795—807.
88.
Tomatis, L., Huff, J., Hertz-Picciotto, I., Sandler, D.P., Bucher, J., Boffetta, P., Axelson, O., Blair, A., Taylor, J., Stayner, L., and Barrett, J.C. (1997). Avoided and avoidable risks of cancer. Carcinogenesis18, 97—105.
89.
Tomatis, L., Melnick, R.L., Haseman, J., Barrett, J.C., and Huff, J. (2001). Alleged misconceptions distort perceptions of environmental cancer risks. FASEB J15, 195—203.
90.
Tsao, M.S., and Grisham, J.W. (1987). Hepatocarcinomas, cholangiocarcinomas, and hepatoblastomas produced by chemically transformed cultured rat liver epithelial cells. A light- and electron-microscopic analysis. Am J Pathol127, 168—81.
91.
Unoura, M., Kaneko, S., Matsushita, E., Shimoda, A., Takeuchi, M., Adachi, H., Kawai, H., Urabe, T., Yanagi, M., Matsui, O., et al. (1993). High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology40, 305—10.
92.
Wagner, B.M. (2003). Food additives and cancer: banging the drum. Toxicol Pathol31, 348—9.
93.
Ward, J.M., Fox, J.G., Anver, M.R., Haines, D.C., George, C.V., Collins, M., Jr., Gorelick, P.L., Nagashima, K., Gonda, M.A., Gilden, R.V., et al. (1994). Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst86, 1222—7.
94.
Wilbourn, J., Haroun, L., Haseltine, E., Kaldor, J., Partensky, C., and Vainio, H. (1986). Response of experimental animals to human carcinogens: an analysis based upon the IARC Monographs programme. Carcinogenesis7, 1853—63.
95.
Wolff, G.L., Gaylor, D.W., Blackwell, B.N., and Moore, G.E. (1991). Bladder and liver tumorigenesis induced by 2-acetylaminofluorene in different F1 mouse hybrids: variation within genotypes and effects of using more than one genotype on risk assessment. J Toxicol Environ Health33, 327—48.
96.
Yamagiwa, K., and Ichikawa, K. (1918). Experimental study of the pathogenesis of carcinoma . Cancer Res3, 1—29.
97.
Zerban, H., Radig, S., Kopp-Schneider, A., and Bannasch, P. (1994). Cell proliferation and cell death (apoptosis) in hepatic preneoplasia and neoplasia are closely related to phenotypic cellular diversity and instability. Carcinogenesis15, 2467—73.
